Benzinga | Sep 18, 2020 07:41AM EDT

Chardan Capital Downgrades Seres Therapeutics to Neutral, Announces $27.5 Price Target

Chardan Capital analyst Gbola Amusa downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and announces $27.5 price target.